Prying open the door to the tobacco industry's secrets about nicotine. The Minnesota tobacco trial

JAMA

Volumn 280, Issue 13, 1998, Pages 1173-1181

  Hurt, Richard D ^a   Robertson, Channing R ^b  

^a MAYO CLINIC   (United States)

^b Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

ADDICTION; CIGARETTE SMOKING; DRUG LEGISLATION; ETHICS; HEALTH CARE POLICY; HEALTH HAZARD; LAW; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; TOBACCO; TOBACCO INDUSTRY; UNITED STATES;

EID: 0032494432     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.13.1173     Document Type: Review

References (97)

1. Glantz SA, Barnes DE, Bero L, Hanauer P, Slade J. Looking through a keyhole at the tobacco industry: the Brown and Williamson documents. JAMA. 1995;274:219-224.
2. Slade J, Bero LA. Hanauer P, Barnes DE, Glantz SA. Nicotine and addiction: the Brown and Williamson documents. JAMA. 1995;274:225-233.
3. Hanauer P, Slade J, Barnes DE, Bero LA, Glantz SA. Lawyer control of internal scientific research to protect against products liability lawsuits: the Brown and Williamson documents. JAMA. 1995;274:234-240.
4. Bero LA, Barnes DE, Hanauer P, Slade J, Glantz SA. Lawyer control of the tobacco industry's external research program: the Brown and Williamson documents JAMA. 1995;274:241-247.
5. Barnes DE, Hanauer P, Slade J, Bero LA, Glantz SA. Environmental tobacco smoke: the Brown and Williamson documents. JAMA. 1995;274:248-253.
6. Todd JS, Rennie D, McAfee RE, et al. The Brown and Williamson documents: where do we go from here? JAMA. 1995;274:256-258.
7. Long GH. MDD report on teenage smokers (14-17). Memo to E. A. Horrigan, Jr RJR, July 22, 1980. Trial exhibit 13101.
8. Johnson RL. Memo to R. A. Pittman, B&W, February 21, 1973. Trial exhibit 13820.
9. Hind JF. Memo to C. A. Tucker, RJR. January 23, 1975. Trial exhibit 12865.
10. Dukes CA. 1975 marketing plans presentation to RJRI board of directors, RJR, September 30, 1974. Trial exhibit 12493.
11. Senkus M (research director). Invalidation of some reports in the research department. Memo to Max Crohn (Legal Department), RJR, 1969. Trial exhibit 26216.
12. Dunn WL. The nicotine receptor program. Memo to R. B. Seligman, Philip Morris, March 21, 1980. Trial exhibit 26227.
13. Stanford LE. Memo to Philip Morris Document Collection File regarding Philip Morris USA product research performed at INBIFO laboratory in Cologne, Germany. Carbon copied to Alfred T. McDonnell (A&P) among others, Philip Morris, December 2, 1993. Trial exhibit 26277.
14. Colby FG. Weekly highlights. Memo to J. Giles, RJR, December 9, 1981. Trial exhibit 26229.
15. Koop CE, Kessler DC, Lundberg GD. Reinventing American tobacco policy: sounding the medical community's voice. JAMA. 1998;279:550-552.
16. Hanners D. Tobacco's promise exemplified early PR: PR firm hired to go on offensive when health concerns surfaced. St Paul Pioneer Press. February 15, 1998:1A, 12A.
17. Wynder EL, Graham EA. Tobacco smoking as a possible etiological factor in bronchiogenic carcinoma. JAMA. 1950;143:329-336.
18. Doll R, Hill AB. Smoking and carcinoma of the lung: a preliminary report. BMJ. 1950;2:739-748.
19. Wynder EL, Graham EA, Croninger AB. Experimental production of carcinoma with cigarette tar. Cancer Res. 1953;13:855-864.
20. Tobacco Industry Research Committee. A frank statement to cigarette smokers, January 4, 1954. Trial exhibit 14145.
21. Tobacco Industry Research Committee meeting, January 18, 1954. Trial exhibit 14127.
22. Bentley HR, Felton DGI, Reid WW. Report on visit to USA and Canada, BAT, April 17-May 12, 1958. Trial exhibit 11028.
23. knopick PC. Memo to W. Kloepfer, Tobacco Institute, September 9, 1980. Trial exhibit 14303.
24. Ellis C. The effects of smoking: proposal for further research contracts with Battelle, BAT, February 13, 1962. Trial exhibit 11938.
25. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1992;61:743-750.
26. Anderson HD. Potassium carbonate. Memo to R. P. Dobson, BAT, August 7, 1964. Trial exhibit 10356.
27. Panzer F. The Roper proposal. Memo to H. Kornegay, Tobacco Institute, May 1, 1972. Trial exhibit 20987.
28. Nowland Organization Inc. SHF Cigarette Marketplace Opportunities Search and Situation Analysis, II: Management Report. Lorillard, December 1976. Trial exhibit 17994.
29. Dunn WL Jr. Jet's money offer. Memo to Dr H. Wakeham, Philip Morris, February 19, 1969. Trial exhibit 10539.
30. Osdene TS. Memo describing a CTR meeting, New York City, January 5, 1978, Philip Morris, January 10, 1978. Trial exhibit 10227.
31. Steele HD. Future consumer reaction to nicotine. Memo to M. J. McCue, B&W, August 24, 1978. Trial exhibit 13677.
32. Mellman AJ. Project recommendations. Memo to R. A. Blott, B&W, March 25, 1983. Trial exhibit 13344.
33. Oldman M. Cigarette smoking, health, and dissonance (Project Libra), BAT, October 18, 1979. Trial exhibit 11102.
34. Spears AW. Lorillard, November 13, 1973. Trial exhibit 14009.
35. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. N Engl J Med. 1994;331:123-125.
36. Smith RE. Memo to J. R. Ave, J. G. Flinn, and A. W. Spears, Lorillard, February 13, 1980. Trial exhibit 10170.
37. Laurene AH. Possible IBT projects. Memo to M. Senkus, RJR, May 24, 1971. Trial exhibit 12777.
38. Brooks GO. Smoker compensation study. Memo to William Telling, BAT, April 7, 1982. Trial exhibit 13668.
39. Creighton DE. Compensation for changed delivery. BAT, June 27, 1978. Trial exhibit 11089.
40. Green SJ. The product in the early 1980s. BAT, March 29, 1976. Trial exhibit 11386.
41. Schumacher S. Nicotine and smoker satisfaction. RJR, 1977. Trial exhibit 12790.
42. Dunn WL Jr. High nicotine, low TPM cigarettes. Memo to R. B. Seligman, Philip Morris, March 24, 1980. Trial exhibit 10529.
43. Dunn WL Jr. Motives and incentives in cigarette smoking. Philip Morris, 1972. Trial exhibit 18089.
44. Teague CE Jr. The nature of the tobacco business and the crucial role of nicotine therein. Research planning memorandum, RJR, April 14, 1972. Trial exhibit 12408.
45. McCormick AD. Smoking and health. BAT, May 3, 1974. Trial exhibit 10602.
46. Osdene TS. Evaluation of major R&D programs. Letter to R. B. Seligman, Philip Morris, August 12, 1980. Trial exhibit 10255.
47. Roberts DL. Memo to Flavor and Biobehavioral Divisions regarding brainstorming session, RJR, October 13, 1983. Trial exhibit 12743.
48. Reuter B. Table, Philip Morris, circa 1992. Trial exhibit 11559.
49. Johnson RR. Comments on nicotine. B&W, 1971. Trial exhibit 13878.
50. Crellin RA, Ferris RP, Greig C, Milner JK. Brainstorming II: what three radical changes might, through the agency of R&D, take place in this industry by the end of the century? BAT, April 11, 1980. Trial exhibit 11361.
51. Griffith RB. Letter to John Kirwan, B&W, September 18, 1963. Trial exhibit 10856.
52. R&D views on potential marketing opportunities. BAT, December 9, 1984. Trial exhibit 11275.
53. Guess HE. Winston B nicotine control. Memo to J. L. McKenzie, RJR, February 5, 1980. Trial exhibit 18182.
54. Ayres CI. Proceedings of the smoking behavior marketing conference, session III. Notes from the GR&DC Nicotine Conference, B&W, July 9-12, 1984. Trial exhibit 13431.
55. Slaven RW. A progress report on nicotine migration and manipulation. Lorillard, February 25, 1982. Trial exhibit 10019.
56. Pepples E. Memo to I. W. Hughes, B&W, 1977. Trial exhibit 26219.
57. RJR/Biosource genetics: joint research agreement. RJR, 1992. Trial exhibit 13222.
58. Y1 product. B&W. Trial exhibit 13671.
59. Benowitz NL, Hall SM, Herning RI, Jacob P III, Jones RT, Osman A-L. Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med. 1983;309:139-142.
60. Robinson JH. Critique of smokers of low yield cigarettes do not consume less nicotine. To A. Rodgman, RJR, July 25, 1983. Trial exhibit 12648.
61. Robinson JH, Pritchard WS. The meaning of addiction: reply to West. Psychopharmacology. 1992;108:411-416.
62. Smoking and health: significance of the Report of the Surgeon General's Committee to Philip Morris Incorporated. Memo to Dr H. Wakeham, Mr Hugh Cullman, Philip Morris, February 18, 1964. Trial exhibit 10322.
63. Short R. A new product. BAT, October 21, 1971. Trial exhibit 10306.
64. Greig CC. Structured creativity group, thoughts by C. C. Greig - R&D Southampton marketing scenario, 1: low CO product; 2: high expanded tobacco cigarette. BAT, early 1970s. Trial exhibit 10683.
65. Goodman B. Marlboro-Marlboro Lights study delivery data. Report to L. F. Meyer, Philip Morris, September 17, 1975. Trial exhibit 11564.
66. Wood DJ. Smoking products research. BAT, January 19, 1977. Trial exhibit 11203.
67. Short PL. Smoking and health item, 7: the effect on marketing. Memo to Fred Haslam, BAT, April 14 and 28, 1977. Trial exhibits 10584 and 10585.
68. Oldman M. Products/consumer interaction: the role of human smoking studies in subjective testing, with particular reference to machine vs. human smoking. BAT, May 19, 1981. Trial exhibit 11357.
69. Centers for Disease Control and Prevention. Filter ventilation levels in selected U.S. cigarettes, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:1043-1047.
70. Kozlowski LT, Goldberg ME, Yost BA, Ahern FM, Aronson KR, Sweeney CT. Smokers are unaware of the filter events now on most cigarettes: results of a national survey. Tob Control. 1996;5:265-270.
71. US Department of Health and Human Services. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee. Washington, DC: US Dept of Health and Human Services, Public Health Service, National Institutes of Health; August 1996. NIH publication 96-4028.
72. Townsend D. Deposition of David Townsend, in the Circuit Court, 4th Judicial Circuit, Duval County, Florida, Case No. 9501820-CA, Division CV-C. Jean Connor, plaintiff, vs R. J. Reynolds Tobacco Company, etc, et al, defendants. October 3, 1994:1-102. Cited by: Kozlowski LT, Goldberg ME, Yost BA, Ahern FM, Aronson KR, Sweeney CT. Smokers are unaware of the filter events now on most cigarettes: results of a national survey. Tob Control. 1996;5:265-270.
73. Townsend D. Deposition of David Townsend, in the Circuit Court, 4th Judicial Circuit, Duval County, Florida, Case No. 9501820-CA, Division CV-C. Jean Connor, plaintiff, vs R. J. Reynolds Tobacco Company, etc, et al, defendants. October 3, 1994:1-102. Cited by: Kozlowski LT, Goldberg ME, Yost BA, Ahern FM, Aronson KR, Sweeney CT. Smokers are unaware of the filter events now on most cigarettes: results of a national survey. Tob Control. 1996;5:265-270.
74. Hirji T. Effect of ventilation on tar delivery. To A. L. Heard, BAT, July 23, 1987. Trial exhibit 12110.
75. Green SJ. Suggested questions for CAC III. BAT, August 26, 1977. Trial exhibit 11390.
76. US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General, 1988. Washington, DC: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control, Office on Smoking and Health; 1988. Publication CDC 88-8406.
77. Creighton DE. The significance of pH in tobacco and tobacco smoke. Report issued by T Hirji, BAT, June 1988. Trial exhibit 12223.
78. Blackhurst JD. Further work on "extractable" nicotine. Report issued by I. W. Hughes, BAT, September 30, 1966. Trial exhibit 17825.
79. Williams RL. Development of a cigarette with increased smoke pH. Liggett, December 16, 1971. Trial exhibit 11903.
80. Ihrig AM. pH of particulate-phase. Memo to C. L. Tucker, Jr, Lorillard, February 8, 1973. Trial exhibit 10095.
81. Woods JD, Harllee GC. Historical review of smoke pH data and sales trends for competitive brand filter cigarettes. RJR, May 10, 1973. Trial exhibit 12337.
82. Rodgman A. Clarification of my 07/22/80 memo on nicotine additives. Memo, RJR, September 8, 1980. Trial exhibit 13212.
83. Cigarette design. BAT, undated document. Trial exhibit 11973.
84. Riehl T, McMurtrie D, Heemann V, et al. Project SHIP: review of progress, November 5-6, 1984. BAT, November 12, 1984. Trial exhibit 10752.
85. Colby FG. Cigarette concept to assure RJR a larger segment of the youth market. Memo to R. A. Blevins, Jr, RJR, December 4, 1973. Trial exhibit 12464.
86. McKenzie JL. Product characterization definitions and implications. Memo to A. P. Ritchy, RJR, September 21, 1976. Trial exhibit 12270.
87. Teague CE. Implications and activities arising from correlation of smoke pH with nicotine impact, other smoke qualities, and cigarette sales. RJR, 1973. Trial exhibit 13155.
88. Chen L. pH of smoke: a review. Lorillard, July 12, 1976. Trial exhibit 10110.
89. Johnson RR. Ammonia technology conference minutes, Louisville, Ky, May 18-19, 1989, B&W, June 12, 1989. Trial exhibit 13069.
90. Schori TR. Free nicotine: its implication on smoke impact. B&W, October 22, 1979. Trial exhibit 2590.
91. Proceedings of the smoking behavior-marketing conference, July 9-12, 1984, session I. To Dr L. C. F. Blackman and Mr A. M. Heath, B&W, July 30, 1984. Trial exhibit 13430.
92. Gregory CF. Observations of free nicotine changes in tobacco smoke/#528. B&W, January 4, 1980. Trial exhibit 13182.
93. Woods JD, Sheets SH. Smoke balance factors and control: RDM report #4. RJR, January 15, 1975. Trial exhibit 12340.
94. The effects of cigarette smoke "pH" on nicotine delivery and subjective evaluations. Philip Morris, June 24, 1994. Trial exhibit 11752.
95. Shaffer D. Ex-tobacco researcher takes Fifth during trial. St Paul Pioneer Press. February 14, 1998. Available at: http://www.pioneerplanet.com/archive/ tobac. Accessed: August 10, 1998.
96. Osdene TS. Undated handwritten note. Trial exhibit 2501.
97. Report of the Scientific Committee on Tobacco and Health. London: Department of Health (United Kingdom); March 1998:9-10.